CODEINE HYDROBROMIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H21NO3.BrH
Molecular Weight	380.276
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

Br.[H][C@@]12OC3=C4C(C[C@H]5N(C)CC[C@@]14[C@@]5([H])C=C[C@@H]2O)=CC=C3OC

InChI

InChIKey=XOXNTPXYPCJBHI-FFHNEAJVSA-N

InChI=1S/C18H21NO3.BrH/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;/h3-6,11-13,17,20H,7-9H2,1-2H3;1H/t11-,12+,13-,17-,18-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C18H21NO3
Molecular Weight	299.3642
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	BrH
Molecular Weight	80.912
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Codeine is an opiate used to manage mild to moderate pain severe enough to require an opioid. Codeine is a selective agonist for the mu opioid receptor and has an affinity to delta and kappa-opioid receptors. In some countries, this drug is regulated under various narcotic control laws, because its chronic use can cause physical dependence. In others, it is available without a medical prescription in combination with paracetamol.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Potency
Mu opioid receptor 221	Agonist 2,678	6.1 µM [EC50]
Kappa-type opioid receptor 60	Agonist 2,678
Delta-type opioid receptor 45	Agonist 2,678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 614	Primary		Approved 8,429	CAPITAL AND CODEINE

C_max

Value	Dose	Analyte	Population
66.9 ng/mL	30 mg single, oral	CODEINE plasma	Homo sapiens
145 ng/mL	60 mg single, oral	CODEINE plasma	Homo sapiens
229 ng/mL	60 mg single, intramuscular	CODEINE plasma	Homo sapiens
93 ng/mL	60 mg single, oral	CODEINE plasma	Homo sapiens
242 ng/mL	60 mg single, intramuscular	CODEINE plasma	Homo sapiens
53.5 ng/mL	30 mg single, oral	MORPHINE-3-GLUCURONIDE plasma	Homo sapiens
66.9 ng/mL	30 mg single, oral	CODEINE plasma	Homo sapiens
968 ng/mL	30 mg single, oral	CODEINE-6-GLUCURONIDE plasma	Homo sapiens

AUC

Value	Dose	Analyte	Population
0.61 μM × h	30 mg single, oral	CODEINE plasma	Homo sapiens
466 ng × h/mL	60 mg single, oral	CODEINE plasma	Homo sapiens
849 ng × h/mL	60 mg single, intramuscular	CODEINE plasma	Homo sapiens
467 ng × h/mL	60 mg single, oral	CODEINE plasma	Homo sapiens
937 ng × h/mL	60 mg single, intramuscular	CODEINE plasma	Homo sapiens

T_1/2

Value	Dose	Analyte	Population
1.47 h	30 mg single, oral	CODEINE plasma	Homo sapiens
2.8 h	60 mg single, oral	CODEINE plasma	Homo sapiens
2.8 h	60 mg single, intramuscular	CODEINE plasma	Homo sapiens
2.7 h	60 mg single, oral	CODEINE plasma	Homo sapiens
2.9 h	60 mg single, intramuscular	CODEINE plasma	Homo sapiens
1.71 h	30 mg single, oral	MORPHINE-3-GLUCURONIDE plasma	Homo sapiens
1.47 h	30 mg single, oral	CODEINE plasma	Homo sapiens
2.75 h	30 mg single, oral	CODEINE-6-GLUCURONIDE plasma	Homo sapiens

F_unbound

Value	Dose	Co-administered	Analyte	Population
75%	15 mg single, oral		CODEINE plasma	Homo sapiens

Doses

Doses

Show entries

Dose	Population	Adverse events
360 mg 1 times / day multiple, oral Highest recorded dose	unhealthy

Showing 1 to 1 of 1 entries

Previous1Next

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1,737 inhibitor 1,587	inhibitor 1,767	substrate 1,217 inhibitor 1,852	inhibitor 1,612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT1 512 UGT2B7 146 CYP19A1 60 CYP1A2 1,524	UGT2B7 389 UGT1A3 422 UGT1A1 418 UGT1A4 347 OCT1 327 UGT2B4 249 UGT1A8 283 UGT1A10 291 P-gp 1,537 UGT2B15 203

Drug as perpetrator

Show entries

Target	Modality	Activity
CYP2D6 1,891	inhibitor 3,277	inconclusive [IC50 35.7774 uM]
CYP19A1 60	inhibitor 3,277	no
CYP1A2 1,692	inhibitor 3,277	no
CYP2C9 1,819	inhibitor 3,277	no
CYP3A4 1,925	inhibitor 3,277	no

Showing 1 to 5 of 7 entries

Previous1 2Next

Drug as victim

Show entries

Target	Modality	Activity
UGT2B4 249	substrate 3,367	major
UGT2B7 389	substrate 3,367	major
P-gp 1,537	substrate 3,367	no
UGT1A10 291	substrate 3,367	no
UGT1A3 422	substrate 3,367	no

Showing 1 to 5 of 13 entries

Previous1 2 3Next

Tox targets

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1,647	inhibitor 1,626

Showing 1 to 1 of 1 entries

Previous1Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
ABI Chem	AC1Q4DTD
Alfa Chemistry	170301
Alfa Chemistry	ACM52453040
AN PharmaTech	AN-23899
Angene	AGN-PC-0U9ZUU

Showing 1 to 5 of 48 entries

Previous1 2 3 4 5…10Next

PubMed

Show entries

Title	Date	PubMed
Codeine analgesia is due to codeine-6-glucuronide, not morphine.	2000 Jul-Aug	11092114
Dystonia as acute adverse reaction to cough suppressant in a 3-year-old girl.	2001	11587381
Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis.	2001	11438043
Saliva testing after single and chronic administration of dihydrocodeine.	2001	11296884
Angle closure risk from proprietary medicines.	2001 Apr	11339612

Showing 1 to 5 of 22 entries

Previous1 2 3 4 5Next

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Oral

Substance Class	Chemical
Record UNII	8HOK0TIN61
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

CODEINE HYDROBROMIDE

Common Name

English

CODEINE HBR

Common Name

English

MORPHINAN-6-OL, 7,8-DIDEHYDRO-4,5-EPOXY-3-METHOXY-17-METHYL-, HYDROBROMIDE (1:1), (5.ALPHA.,6.ALPHA.)-

Common Name

English

MORPHINAN-6-OL, 7,8-DIDEHYDRO-4,5-EPOXY-3-METHOXY-17-METHYL-, HBR (1:1), (5.ALPHA.,6.ALPHA.)-

Common Name

English

Codeine hydrobromide [WHO-DD]

Common Name

English

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Code System

Code

Type

Description

ECHA (EC/EINECS)

204-730-2

PRIMARY

PUBCHEM

5464192

PRIMARY

SMS_ID

100000079771

PRIMARY

EVMPD

SUB13426MIG

PRIMARY

FDA UNII

8HOK0TIN61

PRIMARY

Showing 1 to 5 of 7 entries

Previous1 2Next

Show entries

Related Record

Type

Details


					UX6OWY2V7J

CODEINE ANHYDROUS

PARENT -> SALT/SOLVATE

Showing 1 to 1 of 1 entries

Previous1Next

Show entries

Related Record

Type

Details


					UX6OWY2V7J

CODEINE ANHYDROUS

ACTIVE MOIETY

Showing 1 to 1 of 1 entries

Previous1Next

SMILES

InChI

CNS Activity

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Funbound

Doses

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound

Drug as perpetrator